Cipla inches up on getting USFDA’s final approval for Difluprednate Ophthalmic Emulsion

12 Aug 2021 Evaluate

Cipla is currently trading at Rs. 910.45, up by 0.20 points or 0.02% from its previous closing of Rs. 910.25 on the BSE.

The scrip opened at Rs. 912.00 and has touched a high and low of Rs. 915.00 and Rs. 906.20 respectively. So far 26871 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 997.20 on 30-Jun-2021 and a 52 week low of Rs. 701.50 on 09-Sep-2020.

Last one week high and low of the scrip stood at Rs. 952.85 and Rs. 897.90 respectively. The current market cap of the company is Rs. 73412.53 crore.

The promoters holding in the company stood at 36.72%, while Institutions and Non-Institutions held 41.07% and 22.21% respectively.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (USFDA). Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol.

It is used for the treatment of inflammation and pain associated with ocular surgery and  treatment of endogenous anterior uveitis. According to IQVIA (IMS Health), Durezol had US sales of approximately $106mn for the 12-month period ending June 2021. The product will be available for shipping soon.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1502.00 10.60 (0.71%)
31-Dec-2025 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.00
Dr. Reddys Lab 1266.45
Cipla 1502.00
Zydus Lifesciences 913.10
Lupin 2101.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×